代替療法セグメントは予測期間中に大幅な成長が見込まれています

世界血友病連盟による年次グローバル調査によれば、2020年において、フォン・ウィルブランド病と診断された人の総数は84,197人でした。さらに、いくつかの市場参加者がフォン・ウィルブランド病の治療のための代替療法の承認取得に従事しています。たとえば、2021年6月、武田薬品工業株式会社は、アメリカ食品医薬品局（FDA）がVONVENDI [フォン・ウィルブランド因子（組換え）]の補足生物学的製品許可申請（sBLA）を審査のために受理したと報告しました。これは、フォン・ウィルブランド病を有する成人（18歳以上）の出血エピソードの頻度を予防または減少させるための予防的治療を目的としています。

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場力学

  • 4.1 市場概要

  • 4.2 市場の促進要因

    • 4.2.1 患者支援プログラムの増加

    • 4.2.2 成長する医療費

  • 4.3 市場の抑制要因

    • 4.3.1 認識欠如

    • 4.3.2 高い治療コスト

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 サプライヤーの交渉力

    • 4.4.2 買い手・消費者の交渉力

    • 4.4.3 新規参入の脅威

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメンテーション（市場規模別、金額、百万米ドル）

  • 5.1 疾病タイプ別

    • 5.1.1 タイプ1

    • 5.1.2 タイプ2

    • 5.1.3 タイプ3

    • 5.1.4 後天性VWD

  • 5.2 治療タイプ別

    • 5.2.1 デスモプレシン

    • 5.2.2 代替療法

    • 5.2.3 血栓を安定させる薬

    • 5.2.4 その他の治療法

  • 5.3 投与経路別

    • 5.3.1 オーラル

    • 5.3.2 インジェクション

    • 5.3.3 その他の投与経路

  • 5.4 地域別

    • 5.4.1 北米

      • 5.4.1.1 米国
      • 5.4.1.2 カナダ
      • 5.4.1.3 メキシコ

    • 5.4.2 ヨーロッパ

      • 5.4.2.1 ドイツ
      • 5.4.2.2 英国
      • 5.4.2.3 フランス
      • 5.4.2.4 イタリア
      • 5.4.2.5 スペイン
      • 5.4.2.6 その他ヨーロッパ

    • 5.4.3 アジア太平洋

      • 5.4.3.1 中国
      • 5.4.3.2 日本
      • 5.4.3.3 インド
      • 5.4.3.4 オーストラリア
      • 5.4.3.5 韓国
      • 5.4.3.6 その他アジア太平洋

    • 5.4.4 中東・アフリカ

      • 5.4.4.1 GCC地域
      • 5.4.4.2 南アフリカ
      • 5.4.4.3 その他中東・アフリカ

    • 5.4.5 南米

      • 5.4.5.1 ブラジル
      • 5.4.5.2 アルゼンチン
      • 5.4.5.3 その他南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 CSL Behring

    • 6.1.2 Ferring Pharmaceuticals

    • 6.1.3 Grifols SA

    • 6.1.4 Octapharma AG

    • 6.1.5 Pfizer Inc

    • 6.1.6 Sanofi SA

    • 6.1.7 Takeda Pharmaceutical Company Ltd

    • 6.1.8 Bio Products Laboratory Ltd

• 7 市場機会と今後の動向

The Von Willebrand disease treatment market is expected to register a CAGR of 6.5% during the forecast period (2022-2027).

The COVID-19 pandemic has significantly impacted the Von Willebrand disease treatment market. For instance, as per a September 2021 published article titled, “Role of von Willebrand Factor in COVID-19 Associated Coagulopathy," patients with COVID-19 have significantly elevated levels of the Von Willebrand factor (vWF) antigen, contributing to an increased risk of thrombosis seen in COVID-19 associated coagulopathy (CAC). As per the same source, the high levels of both vWF antigen and activity have been clinically correlated with worse outcomes. Thus, the demand for Von Willebrand disease treatment is anticipated to rise, thereby contributing to market growth. On the other hand, the lack of awareness and the high cost of the treatment are the factors hindering the market growth.

The major factors fueling the market growth are the increase in patient assistance programs and the growing healthcare expenditure.

In July 2021, the PAN Foundation opened a new patient assistance program for people living with the Von Willebrand disease. The patients who qualify for this program receive USD 10,200 per year in financial assistance to pay for the deductibles, co-pays, and coinsurance costs associated with the treatment for the disease. Another initiative is the Octapharma Co-Pay Assistance Program. This program is available through Factor My Way and provides eligible patients with significant savings on some of the costs associated with their treatment. Such programs propel the demand for the treatment of the Von Willebrand disease, thereby contributing to the growth of the market.

Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, lack of awareness and high cost of treatment may hamper the growth of the market.

Key Market Trends

Replacement Therapy Segment Expected to Register Significant Growth Over the Forecast Period

The replacement therapy segment is anticipated to witness significant growth. Replacement therapy is referred to as the therapy involving the supply of a substance (such as a hormone or nutrient) lacking in or lost from the body. The major factors fueling the segment's growth are the number of people with Von Willebrand disease and the increasing number of product approvals.

As per the Annual Global Survey by the World Hemophilia Federation, in 2020, the total number of people identified with the Von Willebrand disease globally was 84,197. In addition, several market players are engaged in obtaining approvals for replacement therapies for the treatment of the Von Willebrand disease. For instance, in June 2021, Takeda Pharmaceutical Company Limited reported that the United States Food and Drug Administration (FDA) had accepted the supplemental Biologics License Application (sBLA) for VONVENDI [von Willebrand factor (Recombinant)] for review. This is meant for prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults (aged 18 years and older) with von Willebrand disease.

Thus, due to the above-mentioned factors, the segment is expected to witness significant growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

Within North America, the United States holds the major share of the market. The major factors contributing to the market growth in the United States are the rising incidence of Von Willebrand disease, the growing number of strategic initiatives, and the growing number of patient assistance programs.

As per the Annual Global Survey by the World Hemophilia Federation, in 2020, the total number of people identified with Von Willebrand disorder in the United States was 8,919. Also, as per an April 2021 update by the Centers for Disease Control and Prevention (CDC), Von Willebrand disease is the most common bleeding disorder in the country. 3.2 million people (or around one person in every 100 people) in the United States have the disease. Therefore, there is a significant demand for the treatment of this disease in the United States, which contributes to the market growth.

There are several initiatives to raise awareness of the Von Willebrand disease. For instance, in August 2020, the National Hemophilia Foundation and Takeda partnered with Alex Borstein to raise awareness regarding the Von Willebrand disease.

Thus, due to the above-mentioned factors, the region is expected to witness significant growth during the forecast period.

Competitive Landscape

The Von Willebrand disease treatment market is competitive, with the presence of many global players. The most prominent players in the market are Bayer AG, CSL Behring, Ferring Pharmaceuticals, Grifols, Octapharma AG, Pfizer, Sanofi, Sun Pharmaceutical, and Takeda.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Increase in Patient Assistance Programs

    • 4.2.2 Growing Healthcare Expenditure

  • 4.3 Market Restraints

    • 4.3.1 Lack of Awareness

    • 4.3.2 High Cost of Treatment

  • 4.4 Porter's Five Forces Analysis

    • 4.4.1 Bargaining Power of Suppliers

    • 4.4.2 Bargaining Power of Buyers/Consumers

    • 4.4.3 Threat of New Entrants

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Disease Type

    • 5.1.1 Type 1

    • 5.1.2 Type 2

    • 5.1.3 Type 3

    • 5.1.4 Acquired VWD

  • 5.2 By Treatment Type

    • 5.2.1 Desmopressin

    • 5.2.2 Replacement Therapies

    • 5.2.3 Clot-stabilizing Medications

    • 5.2.4 Other Treatment Types

  • 5.3 By Route of Administration

    • 5.3.1 Oral

    • 5.3.2 Injection

    • 5.3.3 Other Routes of Administration

  • 5.4 Geography

    • 5.4.1 North America

      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico

    • 5.4.2 Europe

      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe

    • 5.4.3 Asia-Pacific

      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific

    • 5.4.4 Middle East and Africa

      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa

    • 5.4.5 South America

      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 CSL Behring

    • 6.1.2 Ferring Pharmaceuticals

    • 6.1.3 Grifols SA

    • 6.1.4 Octapharma AG

    • 6.1.5 Pfizer Inc

    • 6.1.6 Sanofi SA

    • 6.1.7 Takeda Pharmaceutical Company Ltd

    • 6.1.8 Bio Products Laboratory Ltd

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS